vs
Side-by-side financial comparison of Cyngn Inc. (CYN) and MiNK Therapeutics, Inc. (INKT). Click either name above to swap in a different company.
MiNK Therapeutics, Inc. is the larger business by last-quarter revenue ($111.2K vs $68.1K, roughly 1.6× Cyngn Inc.). On growth, MiNK Therapeutics, Inc. posted the faster year-over-year revenue change (181.1% vs -77.8%). Over the past eight quarters, Cyngn Inc.'s revenue compounded faster (251.5% CAGR vs -12.8%).
Cyngn Inc. is a technology firm specializing in AI-powered autonomous driving solutions for industrial use cases. It develops self-driving software and hardware integration tools for industrial vehicles including forklifts and pallet trucks, serving manufacturing, warehousing, and logistics customers across North America to improve operational efficiency and worksite safety.
MiNK Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative invariant natural killer T (iNKT) cell therapies to treat cancer, autoimmune disorders and other serious unmet medical needs. It targets the global biopharmaceutical market, with core segments covering oncology and immunology, advancing its allogeneic cell therapy pipeline through preclinical and clinical trials.
CYN vs INKT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $68.1K | $111.2K |
| Net Profit | — | $-2.6M |
| Gross Margin | 17.5% | — |
| Operating Margin | — | -2432.3% |
| Net Margin | — | -2339.4% |
| Revenue YoY | -77.8% | 181.1% |
| Net Profit YoY | 87.7% | -5.6% |
| EPS (diluted) | — | $-0.52 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $68.1K | $111.2K | ||
| Q3 25 | $70.0K | $55.2K | ||
| Q2 25 | $33.7K | — | ||
| Q1 25 | $47.2K | — | ||
| Q4 24 | $306.4K | $39.6K | ||
| Q3 24 | $47.6K | $78.0K | ||
| Q2 24 | $8.7K | $38.4K | ||
| Q1 24 | $5.5K | — |
| Q4 25 | — | $-2.6M | ||
| Q3 25 | $-8.4M | $-2.9M | ||
| Q2 25 | $-5.4M | — | ||
| Q1 25 | $-7.6M | — | ||
| Q4 24 | $-16.1M | $-2.5M | ||
| Q3 24 | $-5.4M | $-1.8M | ||
| Q2 24 | $-5.8M | $-2.7M | ||
| Q1 24 | $-6.0M | — |
| Q4 25 | 17.5% | — | ||
| Q3 25 | 27.4% | — | ||
| Q2 25 | 49.8% | — | ||
| Q1 25 | 74.9% | — | ||
| Q4 24 | 18.5% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | -2432.3% | ||
| Q3 25 | -12028.9% | -5772.5% | ||
| Q2 25 | -16313.4% | — | ||
| Q1 25 | -11060.0% | — | ||
| Q4 24 | -1808.7% | -6324.0% | ||
| Q3 24 | -11575.7% | -2415.7% | ||
| Q2 24 | -67076.8% | -8005.9% | ||
| Q1 24 | -108223.5% | — |
| Q4 25 | — | -2339.4% | ||
| Q3 25 | -12059.9% | -5236.0% | ||
| Q2 25 | -16154.6% | — | ||
| Q1 25 | -16102.9% | — | ||
| Q4 24 | -5261.2% | -6224.0% | ||
| Q3 24 | -11405.9% | -2315.7% | ||
| Q2 24 | -67154.7% | -7043.3% | ||
| Q1 24 | -108290.9% | — |
| Q4 25 | — | $-0.52 | ||
| Q3 25 | $-1.20 | $-0.65 | ||
| Q2 25 | $-2.70 | — | ||
| Q1 25 | $-6.60 | — | ||
| Q4 24 | $-1079.39 | $-0.57 | ||
| Q3 24 | $-408.30 | $-0.46 | ||
| Q2 24 | $-610.85 | $-0.73 | ||
| Q1 24 | $-422.87 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $34.7M | $13.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $38.8M | $-14.2M |
| Total Assets | $50.1M | $14.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $34.7M | $13.4M | ||
| Q3 25 | $34.9M | $14.3M | ||
| Q2 25 | $39.2M | — | ||
| Q1 25 | $16.3M | — | ||
| Q4 24 | $23.6M | $4.6M | ||
| Q3 24 | $812.8K | $6.3M | ||
| Q2 24 | $7.0M | $9.3M | ||
| Q1 24 | $4.8M | — |
| Q4 25 | $38.8M | $-14.2M | ||
| Q3 25 | $38.7M | $-13.5M | ||
| Q2 25 | $46.8M | — | ||
| Q1 25 | $22.1M | — | ||
| Q4 24 | $-1.0M | $-19.6M | ||
| Q3 24 | $6.6M | $-17.6M | ||
| Q2 24 | $9.7M | $-16.6M | ||
| Q1 24 | $8.0M | — |
| Q4 25 | $50.1M | $14.2M | ||
| Q3 25 | $49.3M | $15.0M | ||
| Q2 25 | $56.2M | — | ||
| Q1 25 | $24.3M | — | ||
| Q4 24 | $30.1M | $5.7M | ||
| Q3 24 | $8.5M | $7.4M | ||
| Q2 24 | $11.9M | $10.3M | ||
| Q1 24 | $9.8M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-23.6M | $-2.1M |
| Free Cash FlowOCF − Capex | $-24.8M | — |
| FCF MarginFCF / Revenue | -36414.2% | — |
| Capex IntensityCapex / Revenue | 1806.3% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-42.5M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-23.6M | $-2.1M | ||
| Q3 25 | $-4.1M | $-941.3K | ||
| Q2 25 | $-6.3M | — | ||
| Q1 25 | $-6.5M | — | ||
| Q4 24 | $-3.6M | $-1.7M | ||
| Q3 24 | $-5.3M | $-3.0M | ||
| Q2 24 | $-4.4M | $-2.3M | ||
| Q1 24 | $-5.8M | — |
| Q4 25 | $-24.8M | — | ||
| Q3 25 | $-4.6M | — | ||
| Q2 25 | $-6.4M | — | ||
| Q1 25 | $-6.7M | — | ||
| Q4 24 | $-4.0M | — | ||
| Q3 24 | $-5.5M | — | ||
| Q2 24 | $-4.7M | — | ||
| Q1 24 | $-6.1M | — |
| Q4 25 | -36414.2% | — | ||
| Q3 25 | -6552.1% | — | ||
| Q2 25 | -19070.4% | — | ||
| Q1 25 | -14191.4% | — | ||
| Q4 24 | -1291.7% | — | ||
| Q3 24 | -11531.2% | — | ||
| Q2 24 | -54799.1% | — | ||
| Q1 24 | -109824.6% | — |
| Q4 25 | 1806.3% | — | ||
| Q3 25 | 742.5% | — | ||
| Q2 25 | 517.1% | — | ||
| Q1 25 | 378.5% | — | ||
| Q4 24 | 101.7% | — | ||
| Q3 24 | 341.4% | — | ||
| Q2 24 | 4192.3% | — | ||
| Q1 24 | 3886.1% | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
